Review questions intermittent fasting for weight loss

A new review of studies suggests that intermittent fasting offers no significant advantage over traditional dieting or no intervention for weight loss among overweight or obese adults. Researchers analyzed data from 22 trials involving nearly 2,000 participants. While the approach remains popular, experts highlight limitations in the evidence.

Intermittent fasting, a dieting method that alternates between eating and fasting periods, has gained popularity as a strategy for shedding excess weight. Common forms include the 16:8 approach, where individuals fast for 16 hours and eat within an eight-hour window, and the 5:2 method, which involves normal eating five days a week and severe calorie restriction on the other two. The core premise is that time-restricted eating naturally lowers overall calorie consumption.

However, a systematic review published in the Cochrane Database of Systematic Reviews challenges its effectiveness. Led by Luis Garegnani at the Italian Hospital of Buenos Aires in Argentina, the analysis examined 22 randomized controlled trials with almost 2,000 adults aged 18 to 80 from regions including North America, Europe, China, Australia, and South America. All participants were overweight or had obesity.

The findings indicate no meaningful difference in weight loss when comparing intermittent fasting to standard dietary guidance. Against a control group making no changes, the diet also showed no superior results. "Intermittent fasting just doesn’t seem to work for overweight or obese adults trying to lose weight," Garegnani stated in a press release.

Challenges in the data include inconsistencies across studies, complicating definitive conclusions. Even when results were stratified by gender or fasting type, benefits remained elusive. Satchidananda Panda at the Salk Institute for Biological Studies in California critiqued the review, pointing out that most trials failed to verify participant adherence. "If we don’t know whether participants actually followed the intervention, what, exactly, are we systematically reviewing?" he remarked. "It’s a bit like building a cathedral on quicksand and then performing a meta-analysis of the architecture."

The review concentrated solely on weight loss outcomes, leaving other potential health impacts—such as effects on heart disease risk, immunity, gut function, or liver health—unaddressed, as prior research offers mixed signals. Garegnani emphasized that while intermittent fasting might suit some people, it is no panacea. "Intermittent fasting is not a miracle solution," he said. "[It] may be a useful option for some individuals, but it shouldn’t distract from broader, population-level strategies to prevent and manage obesity."

Awọn iroyin ti o ni ibatan

Relieved Crohn's patients in Stanford clinic with fasting-mimicking diet calendar, healthy meals, and positive trial results charts.
Àwòrán tí AI ṣe

Five-day monthly fasting-mimicking diet eased symptoms and inflammation in Crohn’s trial

Ti AI ṣe iroyin Àwòrán tí AI ṣe Ti ṣayẹwo fun ododo

A Stanford Medicine-led randomized trial in the United States found that a five-day-per-month fasting-mimicking diet was linked to improved patient-reported symptoms and lower biological markers of inflammation in adults with mild-to-moderate Crohn’s disease. The results were published in Nature Medicine.

A new Cochrane review of 22 clinical trials shows that intermittent fasting does not lead to greater weight loss than standard diet advice for overweight or obese adults. The analysis, involving nearly 2,000 participants, challenges the popularity of fasting methods amid rising global obesity rates. Researchers emphasize the need for more long-term studies and personalized approaches.

Ti AI ṣe iroyin

A new study from Northwestern Medicine indicates that stopping eating three hours before bed and extending overnight fasting can improve blood pressure, heart rate, and blood sugar control without reducing calorie intake. Participants aligned their eating with natural sleep cycles, leading to measurable cardiometabolic benefits. The research highlights the importance of meal timing relative to sleep.

A randomized controlled trial in 180 adults found that prescribing diets high, regular or low in sweet-tasting foods for six months did not change participants’ liking for sweet taste, body weight, energy intake, or several biomarkers linked to diabetes and cardiovascular disease. The researchers concluded the results do not support public health advice that aims to reduce exposure to sweet-tasting foods regardless of whether sweetness comes from sugar, low-calorie sweeteners, fruit or dairy.

Ti AI ṣe iroyin

Three Cochrane reviews commissioned by the World Health Organization evaluate GLP-1 receptor agonists like tirzepatide, semaglutide, and liraglutide for weight loss in people with obesity. The drugs show substantial weight reduction compared to placebo, but researchers note limitations in long-term data and industry funding influences. Side effects such as nausea are common, raising questions about broader access and safety.

K-pop's glamour hides a dark side of extreme dieting driven by intense beauty expectations. Idols like IU and TWICE's Momo have shared stories of crash diets that led to rapid weight loss but posed serious health risks. While many now advocate against such practices, young fans continue to be influenced by these trends.

Ti AI ṣe iroyin

New research from Turkey shows that men with obesity tend to develop more abdominal fat and liver stress, while women exhibit higher inflammation and cholesterol levels. These findings, presented at the European Congress on Obesity in Istanbul, highlight sex-based differences that could inform personalized treatments. The study analyzed patients treated between 2024 and 2025.

 

 

 

Ojú-ìwé yìí nlo kuki

A nlo kuki fun itupalẹ lati mu ilọsiwaju wa. Ka ìlànà àṣírí wa fun alaye siwaju sii.
Kọ